During the past decade, Polyclinique du Val de Sambre conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Polyclinique du Val de Sambre" are "Non Small Cell Lung Cancer (Squamous or Non Squamous)" (1 trials) and "Stage IV Lung Cancer" (1 trials). Many other conditions were trialed in "Polyclinique du Val de Sambre" in a lesser frequency.

Most popular intervention types in "Polyclinique du Val de Sambre" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Erlotinib" (1 trials), "Fulvestrant" (1 trials), "Gefitinib" (1 trials), "Gemcitabine" (1 trials) and "Induction chemotherapy" (1 trials). Other intervention names were less common.

The vast majority of trials in "Polyclinique du Val de Sambre" are 1 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Polyclinique du Val de Sambre". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Polyclinique du Val de Sambre, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Polyclinique du Val de Sambre, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".